Skip to main content
Infant Bacterial Therapeutics logo

Infant Bacterial Therapeutics — Investor Relations & Filings

Ticker · IBT ISIN · SE0008015259 LEI · 2138008KVBXCRJGP6Z26 ST Manufacturing
Open in API
Filings indexed 212 across all filing types
Latest filing 2025-11-13 Interim / Quarterly Rep…
Country SE Sweden
Listing ST IBT

About Infant Bacterial Therapeutics

https://ibtherapeutics.com/

Infant Bacterial Therapeutics (IBT) is a pharmaceutical company that develops drugs influencing the human infant microbiome to prevent or treat rare diseases. The company's primary focus is on premature infants, addressing urgent medical needs such as necrotizing enterocolitis (NEC), a potentially lethal inflammatory bowel disorder. Its lead drug candidate, IBP-9414, is a New Biological Entity (NBE) currently in a Phase 3 clinical study. IBT also aims to develop treatments for diseases caused by antibiotic-resistant bacteria. The company is developing its medicines for approval by regulatory agencies, including the FDA and EMA.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Infant Bacterial Therapeutics AB (publ) Interim report January 1 – September 30, 2025'. It contains comprehensive financial data, including income statements, cash flow analysis, and balance sheet summaries for the third quarter and the nine-month period ending September 30, 2025. It also includes management commentary, risk disclosures, and operational updates. As it is a formal financial report for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. 9M 2025
2025-11-13 English
Infant Bacterial Therapeutics AB (publ) announces the appointment of the Nomination Committee for the Annual General Meeting 2026
Board/Management Information Classification · 100% confidence The document is a press release announcing the formation and composition of the Nomination Committee for the upcoming 2026 Annual General Meeting. It details the members appointed by major shareholders and provides contact information for shareholder proposals. Since this is a corporate announcement regarding governance and meeting preparation rather than the meeting materials themselves or a formal proxy statement, it falls under the category of general regulatory announcements or governance-related disclosures. Given the specific nature of the announcement, 'RNS' (Regulatory Filings) is the most appropriate fallback category for this type of corporate disclosure.
2025-10-20 English
Infant Bacterial Therapeutics AB (publ) meddelar att valberedningen inför årsstämman 2026 bildats
Board/Management Information Classification · 100% confidence The document is a press release announcing the formation of the nomination committee (valberedningen) for the upcoming 2026 Annual General Meeting. It details the members of the committee and provides contact information for shareholders. Since this is a regulatory announcement regarding corporate governance and meeting preparation, and does not fit into specific categories like 'AGM-R' (which refers to materials presented at the meeting) or 'PSI' (proxy solicitation), it is best classified as a general regulatory filing.
2025-10-20 Swedish
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for Infant Bacterial Therapeutics AB for the period January 1 to June 30, 2025. It contains comprehensive financial statements, management commentary, operational updates, and risk disclosures for the six-month period. It is not an announcement of a report, but the report itself, containing substantive financial data. H1 2025
2025-08-20 Swedish
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report January 1 – June 30, 2025' for Infant Bacterial Therapeutics AB. It contains comprehensive financial data, including income statements, cash flow summaries, and management commentary on business performance and development projects for the specified interim period. It meets the criteria for an Interim/Quarterly Report (IR) as it provides substantive financial analysis and statements for a period shorter than a full fiscal year. H1 2025
2025-08-20 English
Annual General Meeting of Infant Bacterial Therapeutics
AGM Information Classification · 99% confidence The document is explicitly titled 'ANNUAL GENERAL MEETING OF INFANT BACTERIAL THERAPEUTICS' and details the resolutions passed during this meeting, such as the adoption of financial statements, dividend decisions, board member elections, remuneration approvals, and the approval of an employee stock option program. This content directly corresponds to the materials presented or resolved upon at an AGM. Therefore, the appropriate classification is AGM Information (AGM-R). The document length is short (2709 chars) and it references an attachment, but the primary content *is* the summary of the AGM resolutions, making AGM-R more specific than RPA or RNS.
2025-05-08 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.